<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156324">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01819792</url>
  </required_header>
  <id_info>
    <org_study_id>PI2011-843-0005</org_study_id>
    <nct_id>NCT01819792</nct_id>
  </id_info>
  <brief_title>Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia</brief_title>
  <acronym>LAMVIRE</acronym>
  <official_title>Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infectious morbidity and mortality is a major complication of AML (Acute Myeloid Leukemia)
      induction and consolidation chemotherapies related aplasia. The main aim of this study is to
      measure incidence of respiratory viral infections during AML induction and consolidation
      chemotherapy related aplasia. Primary end point is a positive polymerase chain
      reaction(PCR)associated with clinical signs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bacterial and fungal infection treatment is well defined with guidelines. Few data are
      available for viral infections and concern essentially allogeneic stem cell transplantation.
      These infections are associated with a high mortality and morbidity rate. Data concerning
      AML are essentially retrospective, pediatric and with a little number of patients.
      Respiratory viral infections incidence is not known. These infections may be responsible for
      a higher mortality rate. Different risk factors are found: age superior to 65 years,
      lymphopenia, co-infections. Treatment is subject to a controversy: surveillance or starting
      an antiviral therapy. This study aims at understanding viral infections epidemiology during
      long term aplasia and optimizing their management.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>positivity of the viral PCR in the presence of clinical signs during periods of positivity of the PCR in the presence of clinical signs</measure>
    <time_frame>at day 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>Positivity of the viral PCR in the presence of clinical signs during periods of Aplasia following chemotherapy induction and consolidation defining viral infection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>seasonal viral infection incidence measure</measure>
    <time_frame>18 months after inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>risk factor of viral infections research</measure>
    <time_frame>18 months after inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>viral infections related morbidity and mortality estimation</measure>
    <time_frame>18 months after inclusion</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bacterial and fungal co-infection estimation</measure>
    <time_frame>18 months after inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>description of antiviral therapeutic used for treating patients</measure>
    <time_frame>18 months after inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>patient with Acute Myeloïd Leukemia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Multiplex respiratory viral PCR</intervention_name>
    <arm_group_label>patient with Acute Myeloïd Leukemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years old with an AML diagnostic and treated with induction and
             consolidation chemotherapy. Patients enrolled in another protocol may be included.

          -  Patients with relapsed leukemia who are treated with a salvage intensive therapy stay
             in the study

          -  Patients who have signed a consent policyholder

        Exclusion Criteria:

          -  patients under 18 years old

          -  patients treated with another treatment than induction and consolidation chemotherapy

          -  pregnant women

          -  patients HIV, HBV or HBC positive

          -  patients with a positive PCR at J1

          -  patients treated with an antiviral treatment or an immunosuppressive treatment for
             another pathology

          -  patients under guardianship

          -  Primitive immunity Deficit
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Pierre MAROLLEAU, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU AMIENS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>FABRICE JARDIN, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU ROUEN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>OUMEDALY RENAN, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU CAEN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BRUNO QUESNEL, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU LILLE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JEAN PIERRE MAROLLEAU, PU-PH</last_name>
    <phone>0322455914</phone>
    <email>marolleau.jean-pierre@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pr Marolleau</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JEAN PIERRE MAROLLEAU, MD PhD</last_name>
      <phone>03-22-45-59-14</phone>
      <email>marolleau.jean-pierre@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU CAEN</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>OUMEDALY RENAN, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>OUMEDALY RENAN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chru Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>BRUNO QUESNEL, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>FABRICE JARDIN, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>FABRICE JARDIN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 4, 2014</lastchanged_date>
  <firstreceived_date>March 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
